The place of laser fluorescence spectroscopy, doppler flowmetry and ultrasound in the diagnosis and assessment of treatment efficacy for plaque scleroderma

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

According to modern ideas, a reasonable choice of an effective method of treating plaque scleroderma is based on the diagnosis of the pathological process prevailing in the tissues (inflammation-sclerosis). Therefore, an urgent problem of a personalized approach to dermatosis therapy is the possibility of an objective assessment of the prevailing process using non-invasive diagnostic methods. The article presents a clinical case of widespread plaque scleroderma in a 66-year-old patient, demonstrating the possibility of using laser fluorescence spectroscopy and laser Doppler flowmetry to determine the degree of activity of the focus and determine the leading pathological process.

We selected three pathological skin foci localized in the abdomen and characterizing three clinical stages of the disease (inflammation, induration, sclerosis). The analysis of fluorescence and laser Doppler flowmetry data showed that in areas clinically defined as inflammation, there is an increase in the average values of the indices of tissue content of porphyrins, lipofuscin and microcirculation index compared with intact skin, while the intensity of collagen fluorescence does not differ significantly. In the induration zone, along with an increase in the fluorescence indices of lipofuscin and porphyrins, there is an increase in the average values of collagen fluorescence indices at effective registration waves. The data obtained by us indicate an active inflammatory process in these foci and the process of fibrosis in the induration zone. In the sclerosis zone, there is an increase in the average values of collagen fluorescence indices compared with intact skin, and the fluorescence of optical markers of inflammation (lipofuscin and porphyrins) do not differ significantly in comparison with the control intact skin. When analyzing the fluorescence spectra and laser Doppler flowmetry data after treatment, we found that in the zones of induration and inflammation, the average values of the fluorescence indices of porphyrins, lipofuscin, collagen and microcirculation index are reduced relative to the initial values (before treatment), but remain higher in comparison with intact skin. The data obtained may indicate that active inflammation in these foci persists at the time of the study. In the study of the focus of sclerosis, the obtained autofluorescence and microcirculation data in dynamics do not differ significantly from the initial values. The data for laser Doppler flowmetry and laser fluorescence spectroscopy are consistent with ultrasound examination of the skin.

In our study, the potential possibility of using laser fluorescence spectroscopy and laser Doppler flowmetry methods to establish the degree of activity of the focus, determine the leading pathological process, as well as to evaluate the effectiveness of therapy was demonstrated for the first time.

Full Text

Restricted Access

About the authors

Evgeniy F. Khynku

Moscow Regional Research and Clinical Institute

Author for correspondence.
Email: Khynky_ev@mail.ru
ORCID iD: 0000-0003-4368-8469
SPIN-code: 2530-1273
Russian Federation, Moscow

Irina A. Raznitsyna

Moscow Regional Research and Clinical Institute

Email: RaznitsynaIA@yandex.ru
ORCID iD: 0000-0003-4145-6947
SPIN-code: 9092-4490

Junior Research Associate

Russian Federation, Moscow

Yulia V. Molochkova

Moscow Regional Research and Clinical Institute

Email: yulia-molochkova@yandex.ru
ORCID iD: 0000-0001-9021-6494
SPIN-code: 2051-0250

MD, Dr. Sci. (Med.), Assistant Professor

Russian Federation, Moscow

Dmitry A. Rogatkin

Moscow Regional Research and Clinical Institute

Email: rogatkin@medphyslab.com
ORCID iD: 0000-0002-7755-308X
SPIN-code: 9130-8111
http://www.medphyslab.ru

MD, Dr. Sci. (Med.), Assistant Professor

Russian Federation, Moscow

Elena V. Selesneva

Moscow Regional Research and Clinical Institute

Email: Selezneva-elena@mail.ru
ORCID iD: 0000-0002-6181-9031
SPIN-code: 9748-6169

MD, Cand. Sci. (Med.), Assistant Lecturer

Russian Federation, Moscow

Alexey A. Glazkov

Moscow Regional Research and Clinical Institute

Email: staaglz@gmail.com
ORCID iD: 0000-0001-6122-0638
SPIN-code: 3250-1882

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Anton V. Molochkov

Moscow Regional Research and Clinical Institute

Email: antmd@yandex.ru
ORCID iD: 0000-0002-6456-998X
SPIN-code: 1883-4452

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

References

  1. Butova YS, Skripkina YK, Ivanova OL. Dermatovenerology. National leadership. Short edition. Moscow: GEOTAR-Media; 2013. Р. 505–513. (In Russ).
  2. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013;15(3):215. doi: 10.1186/ar4230
  3. Clinical guidelines for localized scleroderma. The Russian Society of Dermatovenerologists and Cosmetologists and the Association of Rheumatologists of Russia; 2020. Available from: https://www.rodv.ru/klinicheskie-rekomendacii/. Accessed: 21.08.2022.
  4. Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80.
  5. Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin North Am. 2002;28(3):603–624. doi: 10.1016/s0889-857x(02)00010-8
  6. Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–550. doi: 10.1001/archdermatol.2009.79
  7. Kubanova AA, Kubanov AA, Melekhina LE, Bogdanova EV. Analysis of the state of morbidity of skin and subcutaneous tissue diseases in the Russian Federation for the period 2003–2016. Bulletin Dermatol Venereol. 2017;(6):22–33. (In Russ). doi: 10.25208/0042-4609-2017-93-6-22-33
  8. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–230. doi: 10.1016/j.jaad.2010.05.045
  9. Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017;31(9):1401–1424. doi: 10.1111/jdv.14458
  10. Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016;14(2):199–216. doi: 10.1111/ddg.12724
  11. Mertens JS, Seyger MM, Thurlings RM, et al. Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol. 2017;18(4): 491–512. doi: 10.1007/s40257-017-0269-x
  12. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003. doi: 10.1056/NEJMra0806188
  13. George R, George A, Kumar TS. Update on management of morphea (localized scleroderma) in children. Indian Dermatol Online J. 2020;11(2):135–145. doi: 10.4103/idoj.IDOJ_284_19
  14. Bendeck SE, Jacobe HT. Ultrasound as an outcome measure to assess disease activity in disorders of skin thickening: an example of the use of radiologic techniques to assess skin disease. Dermatol Ther. 2007;20(2):86–92. doi: 10.1111/j.1529-8019.2007.00116.x
  15. Li SC, Liebling MS, Haines KA. Ultrasonography is a sensitive tool for monitoring localized scleroderma. Rheumatology (Oxford). 2007;46(8):1316–1319. doi: 10.1093/rheumatology/kem120
  16. Hoffmann K, Gerbaulet U, el-Gammal S, Altmeyer P. 20-MHz B-mode ultrasound in monitoring the course of localized scleroderma (morphea). Acta Derm Venereol Suppl (Stockh). 1991;164:3–16.
  17. Moiseev AA, Utts SR. Modern methods of diagnosis of limited scleroderma (review). Saratov Sci Med J. 2016;12(3):481–484. (In Russ).
  18. Weibel L, Howell KJ, Visentin MT, et al. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum. 2007;56(10):3489–3495. doi: 10.1002/art.22920
  19. Serup J, Kristensen JK. Blood flow of morphoea plaques as measured by laser-Doppler flowmetry. Arch Dermatol Res. 1984;276(5):322–325. doi: 10.1007/BF00404625
  20. Kalis B, De Rigal J, Léonard F, et al. In vivo study of scleroderma by non-invasive techniques. Br J Dermatol. 1990;122(6):785–791. doi: 10.1111/j.1365-2133.1990.tb06267.x
  21. Chursinova YV, Kulikov DA, Rogatkin DA, et al. Laser fluorescence spectroscopy and optical tissue oximetry in the diagnosis of skin fibrosis. Biomedical Photonics. 2019;8(1):38–45. (In Russ). doi: 10.24931/2413-9432-2019-8-1-38-45
  22. Helmbold P, Fiedler E, Fischer M, Marsch WC. Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol. 2004;31(6):431–440. doi: 10.1111/j.0303-6987.2004.00203.x
  23. Petritskaya EN, Kulikov DA, Rogatkin DA, et al. Use of fluorescence spectroscopy for diagnosis of hypoxia and inflammatory processes in tissue. J Optical Technol. 2015;82(12):810–814. doi: 10.1364/JOT.82.000810
  24. Kaznacheeva EV, Khinku EF, Makmatov-Rys MB, et al. Lipofuscin as a marker of aging, oxidative stress and proteolysis disorders. Bulletin Postgraduate Med Education. 2020;(3):19–23. (In Russ).
  25. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003. doi: 10.1056/NEJMra0806188

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Patient M., born in 1956, localized scleroderma: clinically active focus (hearth-1; the duration of existence is approximately 3 months), represented by a plaque, 2×4 cm in size, with a bright lilac-pink halo of hyperemia, ivory in the center, dense on palpation, with a smooth shiny surface, it is difficult to fold (induration stage).

Download (204KB)
3. Fig. 2. The same patient. Clinically active new focus (hearth-2; duration of existence from 3 to 4 weeks), represented by a bright pink plaque, 1 cm in diameter, with initial clinical signs of induration in the center (inflammation stage).

Download (201KB)
4. Fig. 3. The same patient. Clinically inactive focus (hearth-3; duration of existence >2 years), represented by a plaque, 5×8 cm in size, dense on palpation, white, with areas of hyperpigmentation and signs of atrophy, there is no growth of vellus hair (sclerosis stage).

Download (205KB)
5. Fig. 4. The example of fluorescence spectra at an excitation wavelength of 365 nm (UV-laser), before and after treatment, in the induration zone of the focus-1.

Download (115KB)
6. Fig. 5. The example of fluorescence spectra at an excitation wavelength of 535 nm (green laser) in the induration zone of focus-1 and intact skin.

Download (89KB)
7. Fig. 6. Dynamics of microcirculation index before and after treatment. Solid lines indicate the dynamics of microcirculation index before and after treatment. Dotted lines indicate the difference in microcirculation index between intact skin and areas of inflammation, induration and sclerosis in the foci after treatment. Explanation in the text.

Download (242KB)
8. Fig. 7. Ultrasound study: а ― focus-1 (induration before treatment: dermis thickness 1.402 mm; echogenicity 11); б ― focus-1 (induration after treatment: dermis thickness 1.027 mm; echogenicity 17); г ― intact skin for the focus-1 (dermis thickness 0.8 mm; echogenicity 23); д ― focus-2 (inflammation before treatment: dermis thickness 1.891 mm; echogenicity 8), е ― focus-2 (inflammation after treatment: dermis thickness 1.250 mm; echogenicity 14); ж ― intact skin for the focus-2 (dermis thickness 0.7 mm; echogenicity 20); з ― focus-3 (scar before treatment; dermis thickness 1.2 mm; echogenicity 17); и ― focus-3 (scar after treatment: dermis thickness 1.21 mm; echogenicity 17), к ― intact skin for the focus-3 (dermal thickness 1.313 mm; echogenicity 14). The arrows indicate dermis thickness.

Download (565KB)

Copyright (c) 2022 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г
.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies